Login to Your Account

Five Prime to Gross $64.5M

Five Prime Goes Public in Upsized Offering, Aerie Joins IPO Parade

By Jennifer Boggs
Managing Editor

Thursday, September 19, 2013
This year’s flurry of initial public offering (IPO) activity continued Wednesday, as protein and antibody drug developer Five Prime Therapeutics Inc. priced an upsized offering to gross $64.5 million and ophthalmology firm Aerie Pharmaceuticals Inc. added its name to biotech’s IPO queue.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription